SEC Tracker
Get the app

Rhythm Pharmaceuticals RYTM

Rhythm Pharmaceuticals Q2 FY24: revenue $29.1M; diluted EPS −$0.55

Form
10-Q/A
Filed
Period
Importance
Routine
Document
10-Q/A

Key figures from this report

These are the numbers Rhythm Pharmaceuticals reported for Q2 FY24, the quarter ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$29.1MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$32.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.55No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$161.7MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$29.1MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Rhythm Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Vaxcyte PCVX public float $3.7B, Jun 30, 2025
  2. Dynavax Technologies DVAX
  3. PERRIGO PRGO public float $3.7B, Jun 27, 2025
  4. Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025
  5. Adma Biologics ADMA public float $4.2B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.